Wellington Management Group LLP Sells 871 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Wellington Management Group LLP trimmed its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,913 shares of the company’s stock after selling 871 shares during the period. Wellington Management Group LLP’s holdings in Amphastar Pharmaceuticals were worth $490,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of AMPH. Signaturefd LLC boosted its holdings in Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock valued at $25,000 after acquiring an additional 520 shares during the period. IFP Advisors Inc bought a new stake in Amphastar Pharmaceuticals during the first quarter valued at about $34,000. GF Fund Management CO. LTD. bought a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at about $38,000. GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 46.6% during the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock valued at $39,000 after acquiring an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC boosted its holdings in Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock valued at $43,000 after acquiring an additional 348 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AMPH shares. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $30.00 target price (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Wells Fargo & Company reduced their target price on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, May 8th. Bank of America increased their target price on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Finally, Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research note on Tuesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of “Hold” and an average target price of $31.60.

Amphastar Pharmaceuticals Stock Up 1.2%

Shares of AMPH opened at $30.62 on Tuesday. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of 11.47 and a beta of 0.80. The company has a quick ratio of 2.21, a current ratio of 3.29 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $53.96. The company has a 50-day moving average price of $24.72 and a two-hundred day moving average price of $25.71.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.